Lenalidomide-Associated ITP

Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. The common toxicities of lenalidomide, including dose-limiting myelosuppression, are well described. However, the immunomodulatory properti...

Descripción completa

Detalles Bibliográficos
Autores principales: Herold, Christina I., Gasparetto, Cristina, Arepally, Gowthami M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420444/
https://www.ncbi.nlm.nih.gov/pubmed/22937309
http://dx.doi.org/10.1155/2011/638020
_version_ 1782240848075816960
author Herold, Christina I.
Gasparetto, Cristina
Arepally, Gowthami M.
author_facet Herold, Christina I.
Gasparetto, Cristina
Arepally, Gowthami M.
author_sort Herold, Christina I.
collection PubMed
description Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. The common toxicities of lenalidomide, including dose-limiting myelosuppression, are well described. However, the immunomodulatory properties of lenalidomide may give rise to unexpected autoimmune complications. Herein, we describe a case of immune thrombocytopenic purpura (ITP) associated with use of lenalidomide.
format Online
Article
Text
id pubmed-3420444
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-34204442012-08-30 Lenalidomide-Associated ITP Herold, Christina I. Gasparetto, Cristina Arepally, Gowthami M. Case Rep Hematol Case Report Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. The common toxicities of lenalidomide, including dose-limiting myelosuppression, are well described. However, the immunomodulatory properties of lenalidomide may give rise to unexpected autoimmune complications. Herein, we describe a case of immune thrombocytopenic purpura (ITP) associated with use of lenalidomide. Hindawi Publishing Corporation 2011 2011-07-17 /pmc/articles/PMC3420444/ /pubmed/22937309 http://dx.doi.org/10.1155/2011/638020 Text en Copyright © 2011 Christina I. Herold et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Herold, Christina I.
Gasparetto, Cristina
Arepally, Gowthami M.
Lenalidomide-Associated ITP
title Lenalidomide-Associated ITP
title_full Lenalidomide-Associated ITP
title_fullStr Lenalidomide-Associated ITP
title_full_unstemmed Lenalidomide-Associated ITP
title_short Lenalidomide-Associated ITP
title_sort lenalidomide-associated itp
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420444/
https://www.ncbi.nlm.nih.gov/pubmed/22937309
http://dx.doi.org/10.1155/2011/638020
work_keys_str_mv AT heroldchristinai lenalidomideassociateditp
AT gasparettocristina lenalidomideassociateditp
AT arepallygowthamim lenalidomideassociateditp

Ejemplares similares